

## Biovica's DiviTum®TKa in four posters at SABCS

**Biovica, active in cancer diagnostics, today announced that four abstracts based on studies using the blood test DiviTum®TKa have been accepted as posters at the world's largest breast cancer symposium, SABCS, in early December.**

The abstracts are based on international studies including the comprehensive US SWOG study, the European prospective PYTHIA study, the PROMISE study at the Mayo Clinic and a dosing study of palbociclib at Washington University. In all studies, DiviTum®TKa has been used to monitor the treatment effect in women with metastatic breast cancer.

“It is extremely gratifying that DiviTum®TKa is included in four posters at SABCS. It is an important validation of our test as a possible standard tool in the evaluation of treatment effect in metastatic breast cancer. The results from the SWOG study are the backbone of our ongoing FDA 510 (k) application with the goal of making the test available to US patients in early 2021,” said Anders Rylander, CEO of Biovica.

The San Antonio Breast Cancer Symposium, SABCS, runs December 8-12, 2020.

### Contact

---

Anders Rylander, CEO

Phone: +46-18-444 48 35

E-mail: [anders.rylander@biovica.com](mailto:anders.rylander@biovica.com)

### Biovica – Treatment decisions with greater confidence

---

Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, [info@fnca.se](mailto:info@fnca.se), +46 8 528 00 399. For more information please visit: [www.biovica.com](http://www.biovica.com).

### Attachments

---

[Biovica's DiviTum®TKa in four posters at SABCS](#)